Evidence map›Paper›PMID 32403292›Full record

ArticleInternational journal of molecular sciences2020

The Bacterial Toxin CNF1 Protects Human Neuroblastoma SH-SY5Y Cells against 6-Hydroxydopamine-Induced Cell Damage: The Hypothesis of CNF1-Promoted Autophagy as an Antioxidant Strategy.

Sara Travaglione, Stefano Loizzo, Rosa Vona, Giulia Ballan, Roberto Rivabene, Danila Giordani, Marco Guidotti, Maria Luisa Dupuis, Zaira Maroccia, Monica Baiula and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Effects of theInternational journal of molecular sciences · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sara TravaglioneIstituto Superiore di Sanità, 00161 Rome, Italy.
Stefano LoizzoIstituto Superiore di Sanità, 00161 Rome, Italy.
Rosa VonaIstituto Superiore di Sanità, 00161 Rome, Italy.
Giulia BallanIstituto Superiore di Sanità, 00161 Rome, Italy.
Roberto RivabeneIstituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-3687-969X
Danila GiordaniIstituto Superiore di Sanità, 00161 Rome, Italy.
Marco GuidottiIstituto Superiore di Sanità, 00161 Rome, Italy.
Maria Luisa DupuisIstituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-6051-8261
Zaira MarocciaIstituto Superiore di Sanità, 00161 Rome, Italy.
Monica BaiulaUniversity of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-0363-0633
Roberto RimondiniUniversity of Bologna, 40126 Bologna, Italy.
Gabriele CampanaUniversity of Bologna, 40126 Bologna, Italy.
Carla FiorentiniIstituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0003-1707-6282
Istituto Superiore di Sanità · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several chronic neuroinflammatory diseases, including Parkinson's disease (PD), have the so-called 'redox imbalance' in common, a dynamic system modulated by various factors. Among them, alteration of the mitochondrial functionality can cause overproduction of reactive oxygen species (ROS) with the consequent induction of oxidative DNA damage and apoptosis. Considering the failure of clinical trials with drugs that eliminate ROS directly, research currently focuses on approaches that counteract redox imbalance, thus restoring normal physiology in a neuroinflammatory condition. Herein, we used SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA), a neurotoxin broadly employed to generate experimental models of PD. Cells were pre-treated with the Rho-modulating

Indexed as

AnimalsAntioxidantsApoptosisAutophagyBacterial ToxinsCell Line, TumorCell SurvivalEscherichia coli ProteinsHumansMembrane Potential, MitochondrialMitochondriaNeuroblastomaNeuroprotective AgentsOxidative StressOxidopamineReactive Oxygen SpeciesAntioxidantsBacterial Toxinscytotoxic necrotizing factor type 1Escherichia coli ProteinsNeuroprotective AgentsOxidopamineReactive Oxygen Species6-hydroxydopaminecytotoxic necrotizing factor type 1macroautophagymitochondriaoxidative stressreactive oxygen speciesRho GTP-binding proteins

Identifiers

PMID32403292
PMCPMC7247702
OpenAlexW3021094059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.